Investigational drug · Phase 2
JR-171
Also called: lepunafusp
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mucopolysaccharidosis I.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "JR-171"
First trial start
2021
Oct 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JR-171", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mucopolysaccharidosis I
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "JR-171" as an intervention, largest first.
JCR Pharmaceuticals Co., Ltd.Industry
NCT04227600 · 18 participants · Start Sep 1, 2020 · Primary completion Aug 2, 2022
Drug: JR-171 (lepunafusp alfa) · For: Mucopolysaccharidosis I
Sites: Oakland, California; Porto Alegre, Brazil; São Paulo, Brazil · 6 sites in all
- An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)Completed
JCR Pharmaceuticals Co., Ltd.Industry
NCT04453085 · 14 participants · Start Oct 28, 2021 · Primary completion May 2, 2025
Drug: JR-171 · For: Mucopolysaccharidosis I
Sites: Oakland, California; Porto Alegre, Brazil; São Paulo, Brazil · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.
Harmatz P, Giugliani R, Martins AM, et al. · Mol Ther 2024
- Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice.
Kida S, Koshimura Y, Yoden E, et al. · Mol Ther Methods Clin Dev 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.